RESUMO
Variegate porphyria (VP) is an autosomal dominant disease caused by mutations of the protoporphyrinogen oxidase (PPOX) gene. This porphyria has unique characteristics which can induce acute neurovisceral attacks and cutaneous lesions that may occur separately or together. We herin report a 58-years-old VP patient complicated with cholelithiasis. A sequencing analysis indicated a novel c.40G>C mutation (p.G14R) in the PPOX gene. His cutaneous photosensitivity had been worsening for 3 years before the emergence of cholecystitis and it then gradually improved after cholecystectomy and ursodeoxycholic acid treatment with a slight decline in the porphyrin levels in his blood, urine and stool. In VP patients, a worsening of photosensitivity can thus be induced due to complications associated with some other disease, thereby affecting their porphyrin-heme biosynthesis.
Assuntos
Colelitíase/complicações , Transtornos de Fotossensibilidade/etiologia , Porfiria Variegada/complicações , Porfiria Variegada/fisiopatologia , Colecistectomia , Colelitíase/terapia , Feminino , Humanos , Masculino , Transtornos de Fotossensibilidade/terapia , Protoporfirinogênio OxidaseRESUMO
Nephrogenic systemic fibrosis (NSF) is characterized by systemic fibrosis and abnormal calcification in patients with severe renal dysfunction. It is considered that gadolinium (Gd)-containing contrast agents used for magnetic resonance imaging trigger the development of NSF. However, the causative role of Gd and the mechanism of Gd-induced fibrosis and calcification in NSF are unknown. Recently, it has been known that endothelin-1 (ET-1)/ET receptor (ETR) signalling regulates fibrosis and calcification. The objective was to elucidate the role of ET-1/ETR signalling in Gd-induced fibrosis and calcification in NSF. First, we demonstrated that Gd enhanced proliferation and calcification of human adipose tissue-derived mesenchymal stem cells (hMSC) in vitro. Next, we examined the expression of ET-1 and ETR-A in hMSC using proliferation or calcification assay. ET-1 and ETR-A expression in hMSC treated with Gd were elevated. ET-1/ETR signalling inhibitor, bosentan, inhibited Gd-induced proliferation and calcification of hMSC. In addition, bosentan inhibited Gd-induced phosphorylation of ERK and Akt in hMSC. Plasma ET-1 levels of the patients were significantly higher than these of normal individuals and systemic sclerosis patients. In immunofluorescence staining, the expression of ETR-A in fibroblasts in dermal fibrosis lesion of NSF was increased. We conclude that Gd induces proliferation and calcification of hMSC via enhancement of ET-1/ETR signalling. Our results contribute to understand the pathogenesis of NSF.
Assuntos
Endotelina-1/metabolismo , Dermopatia Fibrosante Nefrogênica/metabolismo , Receptor de Endotelina A/metabolismo , Adolescente , Bosentana , Calcinose/etiologia , Calcinose/metabolismo , Calcinose/patologia , Proliferação de Células/efeitos dos fármacos , Células Cultivadas , Meios de Contraste/efeitos adversos , Antagonistas dos Receptores de Endotelina/farmacologia , Endotelina-1/sangue , Gadolínio/efeitos adversos , Humanos , Imageamento por Ressonância Magnética/efeitos adversos , Masculino , Células-Tronco Mesenquimais/efeitos dos fármacos , Células-Tronco Mesenquimais/metabolismo , Células-Tronco Mesenquimais/patologia , Pessoa de Meia-Idade , Dermopatia Fibrosante Nefrogênica/etiologia , Dermopatia Fibrosante Nefrogênica/patologia , Transdução de Sinais/efeitos dos fármacos , Sulfonamidas/farmacologiaRESUMO
Midkine is a 13-kDa heparin-binding growth factor. It promotes growth, survival, migration and gene expression of various target cells and play roles in many diseases. In normal adult tissues, midkine expression is highly restricted; however, midkine expression levels are high in various malignant tumors. The major biological roles of midkine can be categorized into three areas, namely, the nervous system, cancer and inflammation. Thus far, midkine has not been studied extensively in diseased human skin. We performed immunohistochemistry tests by using anti-midkine antibodies to study the expression of midkine in normal skin and skin samples of 26 different cutaneous diseases. In addition, we investigated the expression pattern of the midkine gene in cultured keratinocytes. In normal skin, midkine expression was observed in the secretory coils of the eccrine sweat glands, outer root sheath and inner root sheath. Among the cutaneous tumors, the majority of keratinocyte-derived neoplasms were positive for midkine. Tumors that were not derived from keratinocytes were negative for midkine. In cultured keratinocytes, the midkine gene was expressed earlier than the genes required for keratinization, for example, cytokeratin 10 and transglutaminase 1. Because midkine is expressed in the keratinized areas of normal skin, neoplasms and inflammation, it may play a role as a modulator of keratinization in the skin.
Assuntos
Citocinas/metabolismo , Dermatite/metabolismo , Queratinócitos/metabolismo , Neoplasias Cutâneas/metabolismo , Diferenciação Celular , Células Cultivadas , Humanos , Queratinócitos/citologia , Midkina , Pele/metabolismoRESUMO
Nephrogenic systemic fibrosis is a fibrosing disorder that affects patients with advanced renal dysfunction and is associated with gadolinium-based contrast media. As the number of reports increase, it is becoming clear that its clinical course and symptoms are various. We describe a 14-year-old boy and 71-year-old man with nephrogenic systemic fibrosis and review the Japanese cases documented thus far. In Japan, there are only 10 cases definitely associated with gadolinium, whereas over 500 cases have been recorded worldwide. We found a remarkable difference in clinical signs among Japanese cases. Some cases showed keratotic papules or plaques on the extremities. This group tended to develop symptoms after a shorter interval following gadolinium exposure. The remainder of the cases presented glossy and smooth surfaces, with symptoms tending to develop after a longer interval following their last gadolinium exposure. The discrepancies between the actual and the estimated number of patients, and the various clinical manifestations can be explained by the comparatively smaller dosage of gadolinium-based contrast agents commonly administrated in Japan, in contrast to the higher dosages administrated in the USA and Europe.